Aspirin Is Related to Worse Clinical Outcomes of COVID-19.
Medicina (Kaunas)
; 57(9)2021 Sep 04.
Article
in English
| MEDLINE | ID: covidwho-1390697
ABSTRACT
Backgroundand Objectives:
Aspirin is used globally to reduce pain and inflammation; however, its effect in patients with coronavirus disease (COVID-19) is not fully investigated and remains controversial. We evaluated the association between aspirin and COVID-19 outcomes using nationwide data from the Korean National Health Insurance System. Materials andMethods:
This was a retrospective observational cohort study that included 22,660 eligible patients who underwent COVID-19 testing in South Korea between 1 January-31 July 2020. We identified all aspirin users prescribed aspirin within two weeks before or after the index date. The primary outcome was positivity for the COVID-19 test, and secondary outcomes included conventional oxygen therapy, intensive care unit, mechanical ventilation, or death. We applied the propensity score matching method to reduce the possible bias originating from the differences in patients' baseline characteristics.Results:
Of those eligible, 662 patients were prescribed aspirin. Among them, 136 patients were on aspirin within two weeks before diagnosis and 526 patients were on aspirin after diagnosis. The COVID-19 test positivity rate was not significantly different according to aspirin use. Aspirin use before COVID-19 was related to an increased death rate and aspirin use after COVID-19 was related to a higher risk of the conventional oxygen therapy.Conclusion:
Aspirin use was associated with adverse effects in COVID-19 patients. Further studies for mechanisms are needed.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Aspirin
/
COVID-19
Type of study:
Cohort study
/
Diagnostic study
/
Experimental Studies
/
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal subject:
Medicine
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS